All News

PsA, PSO, nail

Two Year Guselkumab Benefits in Psoriatic Arthritis

d MedPage Today

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.

Read Article
RheumNow Podcast square

An Ounce of Prevention (2.4.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

Read Article
Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

xray%20spine%20films_0.jpg

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

d Jack Cush, MD

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
2021,year

2021 Rheumatology Year in Review

d Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Pipeline

Emerging Therapies in Spondyloarthritis: A Promising Pipeline

d Olga Petryna, MD

Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

d Janet Pope, MD, MPH, FRCPC

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

d Jack Cush, MD

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
audience learn

Day 4 Report from ACR21

d Jack Cush, MD

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
swethaann23 swethaann23 ( View Tweet)
#Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK

Links:

Janet Pope Janetbirdope ( View Tweet)

IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Janet Pope Janetbirdope ( View Tweet)
IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
TheDaoIndex KDAO2011 ( View Tweet)
Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts

Olga Petryna DrPetryna ( View Tweet)

After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810 https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
ACR Best

ACR21 Best Abstracts We Saw - Day 3 (Monday)

d Jack Cush, MD

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

Read Article
This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24. Reassuring data. @RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
sheila RHEUMarampa ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.

×